Las cepas del bacilo tuberculoso con farmacorresistencia (TB-DR) son más difíciles de tratar que las
farmacosensibles y amenazan el progreso mundial hacia los objetivos establecidos por la Estrategia Fin de
la TB, de la Organización Mundial de la Salud (OMS). Por lo tanto, existe una necesidad imperio...
This document provides a summary of the evidence and recommendations for the use of SL-LPA for the detection of mutations associated with resistance to fluoroquinolones and SLID in patients with RR-TB and/or MDR-TB. The objectives of this policy guidance are to assess and compare the diagnostic accuracy ...
Tuberculosis Resistente a Múltiples Medicamentos/diagnóstico,
Antibióticos Antituberculosos/farmacología,
Técnicas de Sonda Molecular,
Pruebas de Sensibilidad Microbiana,
Fluoroquinolonas/uso terapéutico,
Farmacorresistencia Bacteriana/genética,
Genotipo,
Mutación,
Tuberculosis Resistente a Múltiples Medicamentos/genética,
Mycobacterium tuberculosis/efectos de los fármacos,
Mycobacterium tuberculosis/genética
Tuberculosis (TB) remains a large-scale public health problem. Key global priorities for TB care and control include improving case-detection and detecting cases earlier, including cases of smear-negative disease. This document updates existing WHO policy on the use of molecular LPAs for detecting MTBC a...
The specific objectives were to evaluate the harms to benefits ratio of delamanid in combination with the currently recommended MDR-TB treatment regimen in children. Based on this evaluation, to develop recommendations on the use of delamanid as part of WHO-recommended longer MDR-TB treatment regimens, a...
The aim of this guidance is to provide the interim principles that should guide the use of delamanid in conjunction with WHO-recommended MDR-TB treatment. It also specifies the essential treatment and management conditions for use of this drug, in particular the patient's eligibility criteria and safety ...
WHO estimates that up to half a million new cases of multidrug-resistant tuberculosis (MDR-TB) occur worldwide, each year. Current treatment regimens for MDR-TB present many challenges: treatment lasts 20 months or more, requiring daily administration of drugs that are more toxic, less effective, and far...
This 2011 update of Guidelines for the programmatic management of drug-resistant
tuberculosis is intended as a tool for use by public health professionals working in response
to the Sixty-second World Health Assembly’s resolution on prevention and control of
multidrug-resistant tuberculosis and extensi...
Commercial liquid culture systems and molecular line-probe assays have been endorsed by the World Health Organization (WHO) as gold standards for rapid detection of multidrug-resistant (MDR) tuberculosis (TB); however, because of technical complexity, cost and the requirement for sophisticated laboratory...
Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) increasingly occur in resource-constrained settings. In the context of a national response to MDR- and XDR-TB, health workers in TB clinics (in district hospitals and some accredited health centres) will need t...
This document is intended to provide an interim policy framework for the laboratory component relevant to programmatic implementation of MDR-TB strategies....